熱門資訊> 正文

Pyxis Oncology获得800万美元支付出售专利权

2024-03-27 19:43

Pyxis Oncology (NASDAQ:PYXS) said it has completed the sale of its rights to royalties from the commercialization of Beovu and another asset to Novartis for a one-time cash payment of $8 million.
The company will record the $8 million payment in Q1 2024, and will retain rights to three other antibodies in development by Apexigen's licensees.

More on Pyxis Oncology

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Pyxis Oncology stock rises as it looks to raise $50M through a private placement
Seeking Alpha’s Quant Rating on Pyxis Oncology
Historical earnings data for Pyxis Oncology
Financial information for Pyxis Oncology

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。